September 13th, 2006. Cytogenetic and molecular genetic changes in malignant mesothelioma
Ongoing studies are already applying high-throughput genomic profiling methods in MM. Genetic alterations observed in MM may be useful in differential diagnosis between lung cancer and MM, as diagnostic markers or therapeutic targets, and as indicators of premalignancy for primary prevention and health surveillance.
June 14th, 2006. Preoperative Evaluation of Patients With Malignant Pleural Mesothelioma: Role of Integrated CT-PET Imaging
Specifically, CT-PET detects more extensive disease involvement than that shown by other imaging modalities and is particularly useful in identifying occult distant metastases. This article reviews aspects of imaging performed in the initial staging of patients with MPM according to the International Mesothelioma Interest Group staging system and will emphasize the appropriate role of CT-PET imaging in determining the T, N, and M descriptors.
May 9th, 2006. Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage
Conclusions: Baseline ppH correlates with survival in epithelial mesothelioma patients treated palliatively with pleurodesis by thoracoscopic talc poudrage. This noninvasive test - ppH - should be included when staging patients with malignant mesothelioma. Copyright (c) 2006 S. Karger AG, Basel.
May 5th, 2006. Pleural mesothelioma: imaging contribution
fr Abstract Imaging plays an essential role in management of patients of with pleural mesothelioma. In this article, we discuss the respective roles for ultrasonography, computed tomography, magnetic resonance imaging, and positon emission tomography for the diagnosis, staging, and postherapeutic evaluation of pleural mesothelioma.
March 24th, 2006. Variability in Mesothelioma Tumor Response Classification
Conclusion: The presentation of baseline scan tumor measurements affects measurements acquired on follow-up scans and could influence tumor response classification. The potential utility of semiautomated tumor thickness measurements was shown in the context of measuring tumor response.
March 10th, 2006. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
Alternative response criteria for mesothelioma thickness measurement (−66% for PR, +74% for PD) achieve volumetric equivalence with the RECIST criteria for spherical tumor measurement. Application of the RECIST response criteria to mesothelioma thickness measurements yields PR and PD classifications based on smaller volume changes than for spherical tumors.
January 27th, 2006. Integrated PET/CT: Current Applications and Future Directions
For prostatic cancer, choline derivatives may become useful radiopharmaceuticals. The published literature on the applications of FDG PET/CT in oncology is still limited, but several well-designed studies have demonstrated the benefits of PET/CT.
January 27th, 2006. Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma
Conclusions: Our data show that (18)F-FDG PET/CT fusion imaging can play a relevant role in the staging and treatment planning of MPM patients.
January 9th, 2006. Magnetic resonance imaging in the evaluation of pneumonia
With parallel imaging techniques, MRI examination of the lungs can be performed with short periods of breath holding, which allow for sub-centimeter resolution in the z-axis. Especially for follow-up examinations in immunocompromised patients and, in some instances, for the staging of malignant diseases (malignant pleural mesothelioma, lung cancer, respectively), MRI is very promising and may contribute to a decrease in the radiation exposure of the patients.
December 21st, 2005. Surgical staging and treatment in malignant pleural mesothelioma
Results: In this series two complications were reported: one diaphragmatic hernia and one postpneumonectomy empyema which were solved with re operation; one single case of peri-operative mortality was reported. 5-Years survival data will be available soon. *Videos of every procedure will be shown.
December 3rd, 2005. Fluorescence Detection of Pleural Malignancies Using 5-Aminolaevulinic Acid
Conclusions: FD using 5-ALA in the pleural cavity is feasible with limited side effects when used in addition to white light inspection. It improved visualization of abnormal lesions and led to upstaging in 4 of 15 mesothelioma patients. Key Words: aminolaevulinic acid • fluorescence detection • pleural malignancies • polymeric photonic display
November 28th, 2005. Extended Surgical Staging for Potentially Resectable Malignant Pleural Mesothelioma
Conclusions: Extended surgical staging defines an important subset of patients with unresectable MPM not identified by imaging. Because of the potential morbidity associated with extrapleural pneumonectomy, we advocate that extended surgical staging be performed in all patients with MPM before resection.
October 1st, 2005. Lymphatic Drainage Patterns of Thoracic Malignancies
The different lymphatic drainage patterns for lung cancer, mesothelioma, esophageal cancer, and lymphoma are described. Understanding lymphatic drainage according to nodal stations of the different tumors is critical for the appropriate diagnosis, staging, and treatment of patients with thoracic malignancies.
July 1st, 2005. Prognostic factors in mesothelioma
3] for those in the worst group. The suggestion is that all clinical and biological factors relevant to prognosis should be recorded prospectively in mesothelioma patients selected for clinical trials.
Conclusions: Integrated computed tomography-positron emission tomography increases the accuracy of malignant pleural mesothelioma staging and is important in determining the appropriate therapy in patients being considered for extrapleural pneumonectomy.
March 29th, 2005. Malignant pleural mesothelioma: staging systems
Restaging of mesothelioma after induction therapy is even more complicated and still controversial. The recently described, modified response evaluation criteria in solid tumors (RECIST) criteria are presently the most accurate for response evaluation.
- Home
- About Mes-Line
- Categories
- Contact Us
- Glossary
- Processor
Article Categories
- Full Archive
- Type of Assessment:
- Case Study
- Causation
- Diagnosis & Differentiation
- Epidemiological
- General
- Staging
- Survival
- Symptoms & Symptom Management
- Treatment
- Angiogenesis
- Chemotherapy
- Bevacizumab (Avastatin)
- Carboplatin
- Cisplatin (Platinol ®)
- Coramsine
- Cyclophosphamide
- Cycloplatam
- Docetaxel (Taxotere)
- Doxorubicin
- Epirubicin (Ellence)
- Erlotinib (Tarceva®)
- Gemcitabine (Gemzar)
- Imatinib Mesylate (Gleevec/Glivec)
- Irinotecan
- melphalan
- mitomycin-C
- Oxaliplatin (Eloxatin)
- Oxaliplatine
- paclitaxel
- Pemetrexed (Alimta)
- Raltitrexed (Tomudex)
- Ranpirnase (Onconase)
- Selenite
- Sunitinib
- Taurolidine
- Vinorelbine
- Determining Efficacy
- EGFR
- Gene Therapy
- Immune-based Therapies
- Intraperitoneal Chemotherapy
- Intrapleural Chemotherapy
- Kinase Inhibitors
- New & Novel
- Photodynamic Therapy (PDT)
- pleurodesis
- Proteasome inhibitors
- Radiation
- Radiofrequency Ablation
- Signal Transduction Inhibitors
- Surgery
- Trimodality Therapy
- Type of Mesothelioma:
Annual Archives:
-
You are currently browsing the archives for the Staging category.
